Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target
Baraka Simon Mayamba, Abdallah Iddy Chaurembo, Francis Chanda, Xu Zheng, Yun-tao Liang, Wen-hui Deng, Yue Liu, Zi-feng Huang, Yong-fang Lin, Na Xing, Peter P. Liu, Han-bin Lin Acta Pharmacologica Sinica
· Springer Nature
· 2026-11-10
· DOI: 10.1038/s41401-026-01954-y
Аннотация
Acta Pharmacologica Sinica, Published online: 10 November 2026; doi:10.1038/s41401-026-01954-y Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target
Baraka Simon Mayamba, Abdallah Iddy Chaurembo, Francis Chanda, Xu Zheng, Yun-tao Liang, Wen-hui Deng et al. Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target. // Acta Pharmacologica Sinica. – 2026. – DOI: 10.1038/s41401-026-01954-y. – URL: https://www.nature.com/articles/s41401-026-01954-y
Baraka Simon Mayamba, Abdallah Iddy Chaurembo, Francis Chanda, Xu Zheng, Yun-tao Liang, Wen-hui Deng, Yue Liu, Zi-feng Huang, Yong-fang Lin, Na Xing, Peter P. Liu, & Han-bin Lin (2026). Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01954-y
Baraka Simon Mayamba, et al. “Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01954-y.
@article{Mayamba2026,
title = {Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target},
author = {Mayamba, Baraka Simon and Chaurembo, Abdallah Iddy and Chanda, Francis and Zheng, Xu and Liang, Yun-tao and Deng, Wen-hui and Liu, Yue and Huang, Zi-feng and Lin, Yong-fang and Xing, Na and Liu, Peter P. and Lin, Han-bin},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01954-y},
url = {https://www.nature.com/articles/s41401-026-01954-y}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...